KMT2A and acute myeloid leukemia: In this context, pinometostat, a small-molecule inhibitor of DOT1L, is being tested in a Ib/II clinical trial along with standard chemotherapy on patients with newly diagnosed acute myeloid leukemia with MLL gene rearrangement (NCT03724084).